| Literature DB >> 33539755 |
Renée L Mulder1, Anna Font-Gonzalez2, Eline van Dulmen-den Broeder3, Gwendolyn P Quinn4, Jill P Ginsberg5, Erik A H Loeffen6, Melissa M Hudson7, Karen C Burns8, Hanneke M van Santen9, Claire Berger10, Tamara Diesch11, Uta Dirksen12, Aleksander Giwercman13, Clarisa Gracia14, Sarah E Hunter15, Joanne F Kelvin16, James L Klosky17, Joop S E Laven18, Barbara A Lockart19, Sebastian J C M M Neggers20, Michelle Peate21, Bob Phillips22, Damon R Reed23, Eva Maria E Tinner24, Julianne Byrne25, Margreet Veening3, Marleen van de Berg26, Chris M Verhaak27, Antoinette Anazodo28, Kenny Rodriguez-Wallberg29, Marry M van den Heuvel-Eibrink30, Ogechukwu A Asogwa31, Alexandra Brownsdon32, W Hamish Wallace33, Daniel M Green7, Roderick Skinner34, Riccardo Haupt35, Lisa B Kenney36, Jennifer Levine37, Marianne D van de Wetering31, Wim J E Tissing38, Norbert W Paul4, Leontien C M Kremer2, Julia Inthorn39.
Abstract
Patients with childhood, adolescent, and young adult cancer who will be treated with gonadotoxic therapies are at increased risk for infertility. Many patients and their families desire biological children but effective communication about treatment-related infertility risk and procedures for fertility preservation does not always happen. The PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group reviewed the literature and developed a clinical practice guideline that provides recommendations for ongoing communication methods for fertility preservation for patients who were diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger and their families. Moreover, the guideline panel formulated considerations of the ethical implications that are associated with these procedures. Grading of Recommendations Assessment, Development and Evaluation methodology was used to grade the evidence and recommendations. In this clinical practice guideline, existing evidence and international expertise are combined to develop transparent recommendations that are easy to use to facilitate ongoing communication between health-care providers and patients with childhood, adolescent, and young adult cancer who might be at high risk for fertility impairment and their families.Entities:
Year: 2021 PMID: 33539755 DOI: 10.1016/S1470-2045(20)30595-7
Source DB: PubMed Journal: Lancet Oncol ISSN: 1470-2045 Impact factor: 41.316